Cuprina Holdings (Cayman) LTD CUPR

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.42

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
Revenue $38.8K$35.5K——
Cost of revenue $39.3K$37.7K——
Gross profit -$501-$2.2K——
R&D $176.4K$177.4K$177.4K—
SG&A $3.6M$1.0M——
Total operating expenses $3.8M$1.2M——
Operating income -$3.8M-$1.2M——
Interest expense $11.4K$6.1K——
Pre-tax income -$3.6M-$1.1M——
Net income -$3.6M-$1.1M——
EPS, basic -1.42-6.38——
EPS, diluted -1.42-6.38——
Shares, diluted (wtd. avg.) 2.6M2.2M2.2M18.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $2.4M$85.6K——
Receivables $14.2K$19.4K——
Inventory —$1.3K——
Total current assets $5.7M$1.2M——
Property, plant and equipment $60.3K$42.7K——
Total assets $6.6M$1.3M——
Accounts payable $915———
Short-term debt $30.1K$40.6K——
Total current liabilities $2.4M$4.4M——
Long-term debt $98.1K$120.4K——
Total liabilities $2.7M$4.6M——
Retained earnings -$7.2M-$3.4M——
Total equity $3.9M-$3.3M-$3.3M—

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$7.1M-$908.6K——
Depreciation and amortisation $28.4K$31.0K——
Capital expenditure $45.3K$16.1K——
Investing cash flow -$45.3K-$16.1K——
Financing cash flow $9.5M$985.8K——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-032280.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -4M -3M -2M -1M 0 1M Revenue, FY2024: 35.5K Gross profit, FY2024: -2.2K Net income, FY2024: -1.1M Revenue, FY2025: 38.8K Gross profit, FY2025: -501 Net income, FY2025: -3.6M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — — $35.5K $38.8K
Gross profit — — -$2.2K -$501
Net income — — -$1.1M -$3.6M

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $159.78B 57.5x 20.5%
EW Edwards Lifesciences Corp $51.34B 48.7x 11.5%
STE STERIS plc $22.63B 29.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.80B 27.8x 7.2%
ALGN ALIGN TECHNOLOGY INC $10.98B 27.3x 0.9%
MSA MSA Safety Inc $7.03B 25.7x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $1.90B — 27.1%
CDRE Cadre Holdings, Inc. $1.28B 29.4x 7.5%